Galecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.
Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment.
Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.
AI Generated. May Contain Errors.
Free DMRA Stock Alerts